AS PER Invoice AS Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: AS PER Invoice AS Pharmaceutical Import Records from India — 3 Products, $115.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AS PER Invoice AS — Pharmaceutical Importer Profile (2026) | 3 Products, $115.7K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to AS PER Invoice AS?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Vama Lifecare Private Limited	$479.1K	192	76.1%
Vama Health World Llp	$150.7K	40	23.9%

AS PER Invoice AS sources from 2 verified Indian suppliers across 179 distinct formulations. Total import value: $629.8K across 232 shipments.

What Formulations Does AS PER Invoice AS Import?

Formulation	Value	Ships
Harmless medicine for human consumptiondaratumumab concentrate for solution forinfusion 400MG/20ML batch no.	$40.2K	1
Harmless medicine for human consumptiondorzolamide & timolol eye drops i.p. 5mlbatch no. 23159 manufacturing date.	$33.0K	1
Harmless medicine for human consumptionsomatropin 36iu batch no. gt3012 manufacturing date. 08/2022 exp date.	$26.7K	1
Harmless medicine for human consumptionetanercept 50MG batch no. gr5514 manufacturing date. 04/2023 exp date.	$25.9K	2
Harmless medicine for human consumptiontabs. valsartan 160MG batch no. b8968a manufacturing date. 05/2023 exp date.	$24.9K	1
Harmless medicine for human consumptiontube. conjugated estrogen vaginal cream14 g batch no. d95n manufacturing date.

What Products Does AS PER Invoice AS Import?

Top Products by Import Value

1Daratumumab$74.3K 2Olaparib$33.9K 3Nilotinib$7.6K

AS PER Invoice AS Therapeutic Categories — 1 Specializations

AS PER Invoice AS imports across 1 therapeutic categories, with Advanced Oncology (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Advanced Oncology

3 products · 100.0% · $115.7K

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Daratumumab	Advanced Oncology	$74.3K	3	5.6%	2
2	Olaparib	Advanced Oncology	$33.9K	9	3.7%	3

Key Metrics

Total Import Value$115.7K

Products3

Shipments15

Categories1

CountryBrazil

#1 Rankings0

Indian Suppliers2

Formulations179

Top Categories

Advanced Oncology100.0%

Indian Suppliers

Last updated: March 28, 2026

AS PER Invoice AS — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

AS PER Invoice AS is a pharmaceutical importer based in Brazil, specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has engaged in 15 shipments from India, totaling an import value of $116,000 USD. The imported products span three distinct formulations within a single therapeutic category, Advanced Oncology, indicating a focused approach to its product portfolio. The top three imported products are Daratumumab ($74,000 USD), Olaparib ($34,000 USD), and Nilotinib ($8,000 USD), collectively accounting for 100% of the company's imports. This concentration suggests a strategic emphasis on oncology treatments, particularly in the realm of advanced cancer therapies.

2Distribution Network

While specific details regarding AS PER Invoice AS's warehouse locations and logistics capabilities are not publicly available, the company's import activities indicate a reliance on efficient distribution networks to manage the importation and distribution of pharmaceutical products. Given the specialized nature of the imported products, it is likely that the company collaborates with logistics providers experienced in handling pharmaceutical goods, ensuring compliance with Brazil's stringent regulatory requirements. The geographic coverage within Brazil is not explicitly detailed, but the focus on advanced oncology products suggests a targeted distribution strategy, potentially serving major urban centers and healthcare facilities equipped to handle such specialized treatments.

Supplier Relationship Intelligence — AS PER Invoice AS

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

AS PER Invoice AS demonstrates a high degree of supplier concentration, with 100% of its imports sourced from two Indian suppliers: VAMA LIFECARE PRIVATE LIMITED ($479,000 USD, 76.1% of shipments) and VAMA HEALTH WORLD LLP ($151,000 USD, 23.9% of shipments). This sourcing strategy indicates a strategic choice to establish strong, reliable partnerships with these suppliers, ensuring consistent product quality and supply chain stability. The significant volume of imports from these two suppliers suggests a deep integration and mutual trust, which can lead to favorable terms and prioritized service. However, this concentration also presents a potential risk; any disruptions affecting these suppliers—such as production issues, regulatory challenges, or geopolitical events—could impact AS PER Invoice AS's ability to meet market demand. To mitigate this risk, the company may consider diversifying its supplier base or developing contingency plans to ensure a continuous supply of critical oncology medications.

2Supply Chain Resilience

The resilience of AS PER Invoice AS's supply chain is closely tied to the stability and reliability of its primary suppliers in India. The company's focus on a limited number of suppliers suggests a deep integration, which can lead to streamlined operations and favorable terms. However, this reliance also means that any disruptions affecting these suppliers—such as production delays, regulatory changes, or logistical challenges—could significantly impact AS PER Invoice AS's ability to fulfill its commitments to the Brazilian market. To enhance supply chain resilience, the company might consider establishing relationships with additional suppliers, implementing robust contingency plans, and closely monitoring the regulatory environments in both India and Brazil to anticipate and mitigate potential disruptions.

3Strategic Implications

The concentrated sourcing strategy of AS PER Invoice AS, focusing exclusively on advanced oncology treatments from two primary suppliers in India, positions the company as a specialized importer catering to a niche market segment in Brazil. This focus allows the company to develop deep expertise and strong relationships within the oncology sector, potentially leading to competitive advantages such as preferential pricing, prioritized service, and a reputation for reliability among healthcare providers. For Indian exporters, this presents an opportunity to establish or strengthen partnerships with AS PER Invoice AS, particularly if they can offer high-quality oncology products that meet the specific needs of the Brazilian market. However, the limited supplier base also means that AS PER Invoice AS is vulnerable to supply chain disruptions. Indian exporters seeking to become alternative suppliers should ensure they can meet the stringent quality standards and regulatory requirements of both India and Brazil, and be prepared to offer competitive pricing and reliable delivery schedules to gain AS PER Invoice AS's trust and business.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the regulation of pharmaceutical products is overseen by the Agência Nacional de Vigilância Sanitária (ANVISA), the National Health Surveillance Agency. ANVISA is responsible for ensuring the safety, efficacy, and quality of health-related products and services, including the authorization of clinical trials, active pharmaceutical ingredients (APIs), and the marketing authorization of drugs and biological products. The agency categorizes drugs into various groups, such as new synthetic and semi-synthetic drugs, generic drugs, similar drugs (branded generics), and others, each subject to specific regulatory pathways. For foreign companies, including Indian exporters, to market their products in Brazil, they must establish a partnership with a legally constituted company in Brazil that will assume legal responsibility for marketing authorization, importing, distribution, and post-marketing surveillance within the country. (gov.br)

2Import Licensing & GMP

Importing pharmaceutical products into Brazil requires compliance with ANVISA's regulations, including obtaining the necessary import licenses and ensuring that products meet Good Manufacturing Practices (GMP). ANVISA's Resolution RDC 658/2022 outlines the general GMP guidelines for medicines, aligning with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standards to ensure product quality and consistency. Foreign companies intending to export pharmaceuticals to Brazil must partner with a Brazilian company that holds the appropriate licenses and authorizations, as ANVISA requires that all imported pharmaceutical products be registered and approved before commercialization. (gov.br)

3Quality & Labeling

Pharmaceutical products imported into Brazil must adhere to ANVISA's quality and labeling requirements. This includes ensuring that products are manufactured in compliance with GMP standards and that labeling is in Portuguese, providing clear and accurate information about the product's composition, dosage, usage instructions, and any necessary warnings. Additionally, ANVISA mandates serialization and traceability of pharmaceutical products to enhance supply chain security and prevent counterfeit products from entering the market. These requirements are part of Brazil's broader efforts to ensure the safety and efficacy of pharmaceutical products available to consumers. (softgroup.eu)

4Recent Regulatory Changes

Between 2024 and 2026, Brazil implemented several regulatory changes affecting pharmaceutical imports. Notably, ANVISA's Resolution RDC 430/2020, which came into force on March 16, 2021, established new Good Distribution Practices for the distribution, storage, and transport of medicines. This regulation unified and updated previous standards, emphasizing the need for temperature and humidity monitoring during the distribution process. The mandatory implementation of these monitoring requirements began on March 17, 2022, necessitating that companies involved in the pharmaceutical supply chain adapt their operations to comply with these stringent conditions.

TransData Nexus Research · Brazil regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: AS PER Invoice AS identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as AS PER Invoice AS's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 15 individual customs records matching AS PER Invoice AS.
5.Supplier Verification: AS PER Invoice AS sources from 2 verified Indian suppliers across 179 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

3 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

AS PER Invoice AS

AS PER Invoice AS — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to AS PER Invoice AS?

What Formulations Does AS PER Invoice AS Import?

What Products Does AS PER Invoice AS Import?

Top Products by Import Value

AS PER Invoice AS Therapeutic Categories — 1 Specializations

Import Portfolio — Top 3 by Import Value

Key Metrics

Top Categories

Indian Suppliers

AS PER Invoice AS — Corporate Profile & Information

1Company Overview

2Distribution Network

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — AS PER Invoice AS

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Brazil — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

AS PER Invoice AS — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to AS PER Invoice AS

1Opportunity Assessment

Frequently Asked Questions — AS PER Invoice AS

What products does AS PER Invoice AS import from India?

Who supplies pharmaceuticals to AS PER Invoice AS from India?

What is AS PER Invoice AS's total pharmaceutical import value?

What therapeutic categories does AS PER Invoice AS focus on?

Get Full AS PER Invoice AS Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology